<DOC>
	<DOCNO>NCT02528747</DOCNO>
	<brief_summary>This observational , multicenter survey design assess efficacy oral ibandronate adult breast cancer metastatic bone disease . Data use ibandronate clinical practice collect Hungarian patient .</brief_summary>
	<brief_title>A Survey Breast Cancer Patients With Metastatic Bone Disease Receiving Oral Ibandronate</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<criteria>Adults least 18 year age Histologically confirm breast cancer bone metastasis Receiving indicate tablet formulation ibandronate accord summary product characteristic ( SmPC ) local label Contraindication ibandronate accord SmPC Ongoing participation trial evaluate efficacy and/or safety ibandronate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>